NCT03998683 (G-PLUS) is a Phase 3 clinical trial of Guselkumab 100 mg in Psoriasis, sponsored by Janssen-Cilag Ltd..

Who is sponsoring NCT03998683?

NCT03998683 is sponsored by Janssen-Cilag Ltd..

What drugs are being tested in NCT03998683?

Interventions in NCT03998683: Guselkumab 100 mg, Placebo.

Is NCT03998683 still recruiting?

NCT03998683 is currently completed. Last updated 3 January 2022.

Last reviewed 2022-01-03 · How we verify

NCT03998683: G-PLUS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis

Completed Phase 3 Last updated 3 January 2022

What this trial tests

Phase 3 trial testing Guselkumab 100 mg in Psoriasis in 117 participants. Completed in 30 November 2021.

Timeline

3 September 2019

Primary endpoint
2 March 2021

30 November 2021

Quick facts

Lead sponsor	Janssen-Cilag Ltd.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	117
Start date	3 September 2019
Primary completion	2 March 2021
Estimated completion	30 November 2021
Sites	26 locations across France, Italy, United Kingdom, Germany, Spain

Drugs / interventions tested

Guselkumab 100 mg — full drug profile →
Placebo

Conditions studied

Psoriasis — all drugs for Psoriasis →

Sponsor

Janssen-Cilag Ltd. — full company profile →

Who can join

18 and older, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy of guselkumab for the treatment of palmoplantar psoriasis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Guselkumab 100 mg

Trials testing the same drug.

NCT03796858 — A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis · Phase 3 · completed
NCT02207231 — A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis · Phase 3 · completed
NCT02207244 — A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Wit · Phase 3 · completed

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting

Other Janssen-Cilag Ltd. trials

Trials by the same sponsor.

NCT07532226 — A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants · not yet recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07242248 — A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disea · recruiting
NCT06472778 — A Real-world Study in Participants With Smoldering Multiple Myeloma · completed
NCT04829669 — A Study of Participants With Moderate or Severe Major Depressive Disorder (MDD) Requiring Urgent Symptom Control in a Ps · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03998683 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen-Cilag Ltd.
Last refreshed: 3 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03998683.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing